Reviva Other Operating Expenses from 2010 to 2025

RVPH Stock  USD 1.37  0.04  2.84%   
Reviva Pharmaceuticals' Other Operating Expenses is increasing with slightly volatile movements from year to year. Other Operating Expenses is estimated to finish at about 47.7 M this year. Other Operating Expenses is expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production. View All Fundamentals
 
Other Operating Expenses  
First Reported
2018-09-30
Previous Quarter
8.1 M
Current Value
8.5 M
Quarterly Volatility
3.9 M
 
Covid
Check Reviva Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Reviva Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 156.3 K, Tax Provision of 10 K or Net Interest Income of 602.5 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 20.25. Reviva financial statements analysis is a perfect complement when working with Reviva Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Reviva Pharmaceuticals Correlation against competitors.

Latest Reviva Pharmaceuticals' Other Operating Expenses Growth Pattern

Below is the plot of the Other Operating Expenses of Reviva Pharmaceuticals Holdings over the last few years. Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Reviva Pharmaceuticals. It is also known as Reviva Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. It is expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production. Reviva Pharmaceuticals' Other Operating Expenses historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Reviva Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Other Operating Expenses10 Years Trend
Slightly volatile
   Other Operating Expenses   
       Timeline  

Reviva Other Operating Expenses Regression Statistics

Arithmetic Mean10,827,989
Geometric Mean1,647,919
Coefficient Of Variation163.89
Mean Deviation14,203,513
Median376,860
Standard Deviation17,746,424
Sample Variance314.9T
Range47.3M
R-Value0.80
Mean Square Error123.2T
R-Squared0.63
Significance0.0002
Slope2,970,120
Total Sum of Squares4724T

Reviva Other Operating Expenses History

202547.7 M
202445.4 M
202339.5 M
202224.3 M
202110.1 M
20202.4 M

About Reviva Pharmaceuticals Financial Statements

Investors use fundamental indicators, such as Reviva Pharmaceuticals' Other Operating Expenses, to determine how well the company is positioned to perform in the future. Although Reviva Pharmaceuticals' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Other Operating Expenses45.4 M47.7 M

Currently Active Assets on Macroaxis

When determining whether Reviva Pharmaceuticals is a strong investment it is important to analyze Reviva Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Reviva Pharmaceuticals' future performance. For an informed investment choice regarding Reviva Stock, refer to the following important reports:
Check out the analysis of Reviva Pharmaceuticals Correlation against competitors.
You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Reviva Pharmaceuticals. If investors know Reviva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Reviva Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.08)
Return On Assets
(3.28)
Return On Equity
(17.95)
The market value of Reviva Pharmaceuticals is measured differently than its book value, which is the value of Reviva that is recorded on the company's balance sheet. Investors also form their own opinion of Reviva Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Reviva Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Reviva Pharmaceuticals' market value can be influenced by many factors that don't directly affect Reviva Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Reviva Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Reviva Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Reviva Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.